검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 21일
현재 선택: 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Stelara (ustekinumab) | Skyrizi (risankizumab) | Anti-IL23 | Anti-IL12/23 |
Overview Company | Janssen | AbbVie | Prof. Dr. Stephan Weidinger | Prof. Dr. Stephan Weidinger |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-12 / IL-23 (p40) | IL-23 (p19) | Atopic Dermatitis | Atopic Dermatitis |
Overview Indication | Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis | Psoriasis, psoriatic arthritis, Crohn's disease | Atopic Dermatitis; Psoriasis | Atopic Dermatitis; Psoriasis |
Overview Phase | APPROVED | APPROVED | PRECLINICAL | PRECLINICAL |
Overview Status | APPROVED | APPROVED | RECRUITING | RECRUITING |
MoA Mechanism | targeting IL-12 family signaling | Blocks IL-23 p19 subunit | on multivariate analysis | with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate response to anti-TNF-α or anti-IL12/2 |
MoA Biomarker | biomarkers but require external validation in independent cohorts | PASI, sPGA | biomarkers of downstream IL23-IL23R activity, are now needed to translate IL23 blockade into the clinic | biomarkers independently predicted survival |
PK/PD Half-life | 19 h | 28 h | — | — |
PK/PD Species | Cynomolgus monkey, NHP, Marmoset | Mouse | Mouse, pharmacodynamics (PD), and antitumor activity. | Mouse |
PK/PD Animal (cat.) | Human, NHP | Mouse | Mouse | Mouse |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | pharmacokinetic | pd |
Toxicology Species | Cynomolgus monkey, NHP, Mouse, Marmoset | Cynomolgus monkey, Mouse | Mouse, pharmacodynamics (PD), and antitumor activity. | Mouse |
Toxicology Animal (cat.) | Mouse, NHP | NHP | Mouse | Mouse |
Toxicology Major finding | — | Hepatotoxicity: Drug-induced liver injury during induction treatment of inflammatory bowel | Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis-A Prospective, Real-World Study From the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).. Mirikizumab (MIRI), an IgG4 monoclonal antibody targeting IL-23 p19, was recently licensed for ulcerative colitis (UC). Most available data come from the pivotal trials, but real-life data are scant. We aimed to evaluate the ef… | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.. Psoriasis is an immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Despite multiple available treatmen… |
Clinical Primary efficacy | ORR 75% | ORR 90% | — | — |
Clinical PASI75 | 67% | PASI90 ~75% (ultIMMa-1) High skin clearance | — | — |
Clinical ORR | PASI75 ~67% (PsO pivotal) | PASI90 ~75% (ultIMMa-1) | — | — |
Clinical Result source | PHOENIX | ultIMMa | — | — |
Clinical Data Tier / Score | S · 91 | B · 91 | C · 22 | C · 16 |
Clinical Program phase | APPROVED | APPROVED | PRECLINICAL | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (3일 전) | 2026년 7월 18일 (3일 전) | 2026년 7월 13일 (9일 전) | 2026년 7월 13일 (9일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 21일
현재 선택: 4개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Stelara (ustekinumab) | Skyrizi (risankizumab) | Anti-IL23 | Anti-IL12/23 |
Overview Company | Janssen | AbbVie | Prof. Dr. Stephan Weidinger | Prof. Dr. Stephan Weidinger |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-12 / IL-23 (p40) | IL-23 (p19) | Atopic Dermatitis | Atopic Dermatitis |
Overview Indication | Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis | Psoriasis, psoriatic arthritis, Crohn's disease | Atopic Dermatitis; Psoriasis | Atopic Dermatitis; Psoriasis |
Overview Phase | APPROVED | APPROVED | PRECLINICAL | PRECLINICAL |
Overview Status | APPROVED | APPROVED | RECRUITING | RECRUITING |
MoA Mechanism | targeting IL-12 family signaling | Blocks IL-23 p19 subunit | on multivariate analysis | with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate response to anti-TNF-α or anti-IL12/2 |
MoA Biomarker | biomarkers but require external validation in independent cohorts | PASI, sPGA | biomarkers of downstream IL23-IL23R activity, are now needed to translate IL23 blockade into the clinic | biomarkers independently predicted survival |
PK/PD Half-life | 19 h | 28 h | — | — |
PK/PD Species | Cynomolgus monkey, NHP, Marmoset | Mouse | Mouse, pharmacodynamics (PD), and antitumor activity. | Mouse |
PK/PD Animal (cat.) | Human, NHP | Mouse | Mouse | Mouse |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | pharmacokinetic | pd |
Toxicology Species | Cynomolgus monkey, NHP, Mouse, Marmoset | Cynomolgus monkey, Mouse | Mouse, pharmacodynamics (PD), and antitumor activity. | Mouse |
Toxicology Animal (cat.) | Mouse, NHP | NHP | Mouse | Mouse |
Toxicology Major finding | — | Hepatotoxicity: Drug-induced liver injury during induction treatment of inflammatory bowel | Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis-A Prospective, Real-World Study From the Sicilian Network for Inflammatory Bowel Disease (SN-IBD).. Mirikizumab (MIRI), an IgG4 monoclonal antibody targeting IL-23 p19, was recently licensed for ulcerative colitis (UC). Most available data come from the pivotal trials, but real-life data are scant. We aimed to evaluate the ef… | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.. Psoriasis is an immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Despite multiple available treatmen… |
Clinical Primary efficacy | ORR 75% | ORR 90% | — | — |
Clinical PASI75 | 67% | PASI90 ~75% (ultIMMa-1) High skin clearance | — | — |
Clinical ORR | PASI75 ~67% (PsO pivotal) | PASI90 ~75% (ultIMMa-1) | — | — |
Clinical Result source | PHOENIX | ultIMMa | — | — |
Clinical Data Tier / Score | S · 91 | B · 91 | C · 22 | C · 16 |
Clinical Program phase | APPROVED | APPROVED | PRECLINICAL | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (3일 전) | 2026년 7월 18일 (3일 전) | 2026년 7월 13일 (9일 전) | 2026년 7월 13일 (9일 전) |
추천 비교
추천 비교